The future of ribosomes

Episode Summary

Executive Summary: This episode of Stanford Engineering's The Future of Everything explores the paradigm-shifting discovery that ribosomes, once thought to be identical, are actually highly diverse molecular machines crucial for health and disease. Host Russ Altman and Professor Maria Barna discuss how ribosomes can consist of hundreds of variations, enabling specialized protein synthesis. They delve into how these 'diabolical ribosomes' can be hijacked in cancer, neurodegenerative diseases, and viral infections, and outline future therapeutic strategies, including ribosome-targeted small molecules and customized ribosomes. The conversation emphasizes the central role of ribosomes in biology and the urgent need to move beyond transcriptomics to understand the proteome.

Main Topics: Ribosome Diversity and Specialization (Priority: 5/5): Ribosomes are not identical; they can have hundreds of types within a cell due to variations in ribosomal RNA, associated proteins, and chemical modifications, enabling them to selectively translate specific mRNAs. Ribosome Hijacking in Disease (Priority: 5/5): Cancer cells, viruses, and neurodegenerative disorders can alter ribosome composition to produce proteins that promote growth, survival, or pathological processes, termed 'diabolical ribosomes'. Limitations of Transcriptomics (Priority: 4/5): RNA sequencing only predicts about 40% of protein expression, highlighting the need to measure the proteome directly to understand cell function and disease. Therapy: Ribosome-Targeted Small Molecules (Priority: 4/5): Screening chemical libraries to find compounds that boost or modify ribosome function is a promising avenue, especially for conditions like neurodegeneration and congenital defects. Customized Ribosomes for Precision Medicine (Priority: 4/5): Using knowledge of the ribosome code to engineer ribosomes that selectively translate therapeutic proteins or kill cancer cells by exploiting their unique ribosome composition. The Ribosome as an Ancient Molecular Machine (Priority: 3/5): Ribosomes are core to life, predating DNA and proteins, and their RNA-based catalytic core supports the RNA world hypothesis. Future Vision: Single-Ribosome Characterization (Priority: 3/5): Developing microfluidics to isolate and characterize individual ribosomes to decode how they select and translate mRNAs, enabling tailored therapies.

Key Arguments: Ribosomes are highly variable molecular machines, not static uniform factories. Ribosome diversity (rRNA variants, protein composition, modifications) enables selective translation of specific mRNAs. Cancer cells hijack ribosomes to produce a customized proteome that supports growth and therapy resistance. Viruses shut down host ribosomes and create dedicated ribosomes for viral protein production. Neurodegenerative diseases and aging involve decline in ribosome activity and composition changes. RNA sequencing alone is insufficient to predict protein expression (only ~40% accuracy). Small molecules can be screened to boost ribosome activity in disease states, analogous to antibiotics targeting bacterial ribosomes. Future therapies could involve engineered ribosomes that selectively kill cancer cells or produce therapeutic proteins.

Data Points: Number of ribosomes per cell: up to 10 million - Typical cell contains up to 10 million ribosomes. Energy dedicated to ribosome production: 60% - 60% of the cell's energy goes into making ribosomes. Percentage of transcriptome encoding ribosomes: 90% - 90% of the transcriptome is ribosomal RNA. Percentage of proteome devoted to ribosome production: 20% - 20% of the proteome is involved in building ribosomes. Possible ribosome variants (theoretical): 10^20 - Potential number of different ribosome types based on known variations. Predictive power of RNA-seq for protein expression: 40% - RNA sequencing only predicts about 40% of actual protein levels. Copies of ribosomal RNA genes: over 500 - There are more than 500 copies of ribosomal RNA genes across five chromosomes.

Pivotal Quotes: "The ribosome is the center of life. Pay attention to your ribosomes. I view the cell as a sack of these ribosomes, and perhaps the most important to think about in both health and disease." — Maria Barna: In response to what she wants people to remember from the episode. "Cancer evolved its customized ribosome to generate a customized cancer proteome. So, now can we put in a payload, for example, something that would kill a cancer cell and make it highly specific only for that cancer cell by making use of those cancer ribosomes?" — Maria Barna: Describing the therapeutic potential of targeting cancer-specific ribosomes. "The future is we can deconstruct and reconstruct life by being able to deconstruct every single ribosome and reconstruct it at will, and use this approach to basically learn about how every single protein in our body is made, and how we can use this as a clever engineering tool for curing diseases." — Maria Barna: Vision for future research and therapeutic applications of ribosome engineering.

Implications: This research suggests a paradigm shift from treating ribosomes as passive factories to dynamic regulators of cellular function. It may lead to novel therapies for cancer, neurodegeneration, and viral infections by targeting or engineering the ribosome. The need for better proteomic tools will drive technology development to complement transcriptomics.